Pembrolizumab-based treatment given through an abdominal port
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase study tests an antibody-based treatment given directly into the abdomen (through a port) for advanced stomach or pancreatic cancer that has spread in the lining of the belly or is causing abdominal fluid buildup. It’s designed for patients whose cancer has not responded to earlier chemotherapy, with the goal of improving cancer control and shrinking belly fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or returning stomach or pancreatic cancer, with spread in the belly lining or belly fluid (ascites) seen on scans
- You may have had several prior chemotherapy treatments (exact number depends on whether you’re in Phase 1 or Phase 2)
- Your tumor is microsatellite stable (MSS) or has normal mismatch repair (pMMR), not MSI-high
- You can have a small abdominal port placed for the treatment
- Your health and organ function are strong enough for treatment (bone marrow, liver, kidneys, and lungs/oxygen tolerance for imaging)
- Your day-to-day functioning is fairly good (ECOG 0–2 for Phase 1, or 0–1 for Phase 2), and you’re expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether changing the gut microbiome (the gut’s helpful bacteria) and giving pembrolizumab after chemotherapy can improve outcomes for people with operable pancreatic cancer. It aims to see if this approach can boost the immune system after standard treatment and help reduce cancer returning.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy (FLOT) for people with advanced stomach or gastroesophageal junction cancer. It may help if your cancer has not been treated before and you are in reasonably good health.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.